Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): A cross-sectional reference study - 18/09/16
Abstract |
Background |
Hidradenitis suppurativa (HS) is a chronic debilitating disease, whereby school attendance and employment can be disturbed.
Objective |
We sought to determine the socioeconomic status (SES) in patients with HS relative to other dermatologic patients, and whether specific clinical HS characteristics correlate with SES.
Methods |
For this multicenter cross-sectional reference study, data were collected from patients with HS and sex- and age-matched dermatologic patients in a 1:2 ratio. SES was derived from the mean household income and real estate value on a neighborhood level.
Results |
The SES distribution among 1018 patients with HS was significantly lower than among 2039 age- and sex-matched dermatologic control patients (P < .001). In patients with HS a low SES was associated with axillary involvement (odds ratio 1.42, P = .04), high body mass index (odds ratio 1.03, P = .003), and lower age at inclusion (odds ratio 0.98, P = .001), but not with disease severity or age of disease onset.
Limitations |
SES was based on postal code level and causality cannot be determined.
Conclusion |
In the general population, low SES is associated with an unhealthy lifestyle such as smoking and obesity. Therefore, low SES might be a risk factor for developing HS.
Le texte complet de cet article est disponible en PDF.Key words : acne inversa, hidradenitis suppurativa, income, obesity, real estate value, smoking, socioeconomic status
Abbreviations used : BMI, CI, HS, OR, SES
Plan
Funding sources: None. |
|
Disclosure: Dr Horváth performed investigator-initiated studies for Janssen-Cilag BV (The Netherlands) and AbbVie Inc, and received an unrestricted educational grant from Abbvie Netherlands (The Netherlands). Further, she has acted as a consultant for AbbVie Inc and Janssen-Cilag BV. Dr Prens acted as a consultant for AbbVie Inc, Amgen, Astra-Zeneca, Baxter, Eli Lilly, Idera, Galderma, Janssen-Cilag BV, Novartis, NTRC, and Pfizer and received investigator-initiated research grants from Pfizer, Janssen-Cilag BV, and AbbVie Inc. Dr Nijsten acted as a consultant for and/or received unrestricted grants from AbbVie Inc, Amgen, Celgene, Eli Lilly, Galderma, Janssen-Cilag BV, Leo Pharma, Novartis, and Pfizer. Dr Boer is on the advisory board of AbbVie Inc. Dr van der Zee received honoraria from AbbVie Inc for participating on the advisory board. Dr Deckers and Janse have no conflicts of interest to declare. |
|
Preliminary results were presented orally at the fifth conference of the European Hidradenitis Suppurativa Foundation in Berlin, Germany, on February 12, 2016. |
Vol 75 - N° 4
P. 755 - octobre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?